Teva's Copaxone faces generic competition in Europe after U.S. hit

LONDON (Reuters) - Teva's blockbuster multiple sclerosis treatment Copaxone will face additional generic competition in Europe, just two days after Mylan NV won U.S. approval to sell cheaper versions of the medicine in the world's largest market.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news